GlassScriptPhysician profile
Jonathan S Richman
NPI 1205994258
$3,629.42
in general payments reported to CMS, 2019-2025
27 companies · $544 in 2025
The $544 reported for 2025 was more than what 75% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $124 · 2020: $88.47 · 2021: $244 · 2022: $214 · 2023: $553 · 2024: $1,862 · 2025: $544.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,804 · Travel and Lodging: $1,059 · Education: $94.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,804.31 |
| Travel and Lodging | $1,059.16 |
| Education | $94.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,238.54 | 2024 | Minimed 780g |
| Abbvie INC. | $482.59 | 2021-2025 | |
| Astellas Pharma US INC | $376.97 | 2020-2025 | Veozah, Myrbetriq |
| Glaxosmithkline, LLC. | $367.62 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Astrazeneca Pharmaceuticals LP | $359.68 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Pfizer INC. | $164.87 | 2020-2025 | |
| Lilly USA, LLC | $125.68 | 2023-2025 | Mounjaro, Zepbound |
| Exact Sciences Corporation | $72.64 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Emd Serono, INC. | $70.71 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $46.01 | 2025 | Rexulti |
| Novo Nordisk INC | $38.82 | 2024-2025 | Wegovy, Rybelsus, Ozempic |
| Janssen Pharmaceuticals, INC | $33.56 | 2021-2022 | |
| Organogenesis INC. | $25.19 | 2024 | |
| Aimmune Therapeutics, INC. | $24.08 | 2025 | Zenpep |
| Biohaven Pharmaceutical Holding Company LTD. | $21.41 | 2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $19.46 | 2023 | Gvoke Hypopen |
| Horizon Therapeutics Plc | $17.54 | 2021 | |
| Nestle Healthcare Nutrition INC. | $17.31 | 2021 | |
| Corcept Therapeutics | $16.63 | 2022 | |
| Axsome Therapeutics, INC. | $15.53 | 2025 | Auvelity |
| Organon LLC | $15.37 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $15.02 | 2020 | |
| Amgen INC. | $13.77 | 2025 | Otezla, Repatha |
| Daiichi Sankyo INC. | $13.56 | 2021 | |
| Eisai INC. | $13.09 | 2021 | |
| Allergan, INC. | $12.47 | 2019 | |
| Gilead Sciences, INC. | $11.30 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Richman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.